Challenges in stem cell-derived islet replacement therapy can be overcome
In this Commentary, we echo the conclusions of a recent review titled “ The promise of stem cell-derived islet replacement therapy ,” which highlighted recent advances in producing glucose responsive “islets” from stem cells and the benefits of their use in islet transplant therapy in type 1 diabete...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-09-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.1177/09636897211045320 |
id |
doaj-b3cf17bc54ff410a83ffbff76ff17896 |
---|---|
record_format |
Article |
spelling |
doaj-b3cf17bc54ff410a83ffbff76ff178962021-09-28T23:20:18ZengSAGE PublishingCell Transplantation1555-38922021-09-013010.1177/09636897211045320Challenges in stem cell-derived islet replacement therapy can be overcomeMidhat H. Abdulreda0Per-Olof Berggren1 Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL, USA The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Karolinska University Hospital L1, Stockholm, SwedenIn this Commentary, we echo the conclusions of a recent review titled “ The promise of stem cell-derived islet replacement therapy ,” which highlighted recent advances in producing glucose responsive “islets” from stem cells and the benefits of their use in islet transplant therapy in type 1 diabetes (T1D). The review also outlined the status of clinical islet transplantation and the challenges that have prevented it from reaching its full therapeutic promise. We agree with the conclusions of the review and suggest that the identified challenges may be overcome by using the eye anterior chamber as an islet transplant site. We anticipate that the combination of stem cell-derived islets and intraocular transplant could help this promising T1D therapy reach full fruition.https://doi.org/10.1177/09636897211045320 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Midhat H. Abdulreda Per-Olof Berggren |
spellingShingle |
Midhat H. Abdulreda Per-Olof Berggren Challenges in stem cell-derived islet replacement therapy can be overcome Cell Transplantation |
author_facet |
Midhat H. Abdulreda Per-Olof Berggren |
author_sort |
Midhat H. Abdulreda |
title |
Challenges in stem cell-derived islet replacement therapy can be overcome |
title_short |
Challenges in stem cell-derived islet replacement therapy can be overcome |
title_full |
Challenges in stem cell-derived islet replacement therapy can be overcome |
title_fullStr |
Challenges in stem cell-derived islet replacement therapy can be overcome |
title_full_unstemmed |
Challenges in stem cell-derived islet replacement therapy can be overcome |
title_sort |
challenges in stem cell-derived islet replacement therapy can be overcome |
publisher |
SAGE Publishing |
series |
Cell Transplantation |
issn |
1555-3892 |
publishDate |
2021-09-01 |
description |
In this Commentary, we echo the conclusions of a recent review titled “ The promise of stem cell-derived islet replacement therapy ,” which highlighted recent advances in producing glucose responsive “islets” from stem cells and the benefits of their use in islet transplant therapy in type 1 diabetes (T1D). The review also outlined the status of clinical islet transplantation and the challenges that have prevented it from reaching its full therapeutic promise. We agree with the conclusions of the review and suggest that the identified challenges may be overcome by using the eye anterior chamber as an islet transplant site. We anticipate that the combination of stem cell-derived islets and intraocular transplant could help this promising T1D therapy reach full fruition. |
url |
https://doi.org/10.1177/09636897211045320 |
work_keys_str_mv |
AT midhathabdulreda challengesinstemcellderivedisletreplacementtherapycanbeovercome AT perolofberggren challengesinstemcellderivedisletreplacementtherapycanbeovercome |
_version_ |
1716865124131667968 |